Stop Calling Low‑Risk Lesions 'Cancer'

Many screen-detected cellular abnormalities (example: prostate grade‑group 1) have negligible short‑term risk of metastasis or death but carry the social, financial and medical burdens associated with the label 'cancer'. Renaming or reclassifying truly indolent lesions and centring informed, surveillance‑first management would reduce overtreatment, psychological harm and health‑system costs. — If adopted, a change in terminology and management for low‑risk lesions would reshape screening guidelines, malpractice risk, insurance coverage, and public expectations about what medical labels mean.